P. A. van der Lubbe

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

P.H. de Jong, Johanna M. W. Hazes, P J Barendregt et al. · Annals of the Rheumatic Diseases · 2012 · 137 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

P.H. de Jong, J. M. W. Hazes, Huub KH Han et al. · Annals of the Rheumatic Diseases · 2014 · 125 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Association of Low Baseline Levels of Erythrocyte Folate With Treatment Nonresponse at Three Months in Rheumatoid Arthritis Patients Receiving Methotrexate

Maurits C. F. J. de Rotte, Pascal H P de Jong, Saskia M.F. Pluijm et al. · Arthritis & Rheumatism · 2013 · 43 citations

Medicine, Clinical Sciences, Internal Medicine +17

Catastrophic manifestation of the antiphospholipid syndrome.

C. G. Schaar, Karel Ronday, ED P.M. BOETS et al. · PubMed · 1999 · 25 citations

Medicine, Hematology, Nephrology +16

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost–utility analysis of the tREACH trial

Pascal H P de Jong, Johanna M. W. Hazes, Leander R. Buisman et al. · Lara D. Veeken · 2016 · 19 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17